SPT vs DSGN vs HUBS vs FULC

For growth investors, HubSpot, Inc.

(HUBS) is the stronger pick with 19. 2% revenue growth year-over-year, versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). HubSpot, Inc. (HUBS) offers the better valuation at 229. 5x trailing P/E (15. 2x forward), making it the more compelling value choice. Analysts rate Sprout Social, Inc. (SPT) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sprout Social, Inc.

is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Fulcrum Therapeutics, Inc.

(FULC) delivered a total return of -30. 0%, compared to -86. 9% for Sprout Social, Inc. (SPT). Over 10 years, the gap is even starker: HUBS returned +359. 7% versus DSGN's -65. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HubSpot, Inc.

(HUBS) is the lower-risk stock at 1. 01β versus Design Therapeutics, Inc. 's 1. 49β — meaning DSGN is approximately 47% more volatile than HUBS relative to the S&P 500. On balance sheet safety, Design Therapeutics, Inc. (DSGN) carries a lower debt/equity ratio of 0% versus 33% for Sprout Social, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), HubSpot, Inc.

(HUBS) is pulling ahead at 19. 2% versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). On earnings-per-share growth, the picture is similar: HubSpot, Inc. grew EPS 863. 0% year-over-year, compared to -637. 5% for Fulcrum Therapeutics, Inc.. Over a 3-year CAGR, HUBS leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HubSpot, Inc.

(HUBS) is the more profitable company, earning 1. 5% net margin versus -9. 5% for Sprout Social, Inc. — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HUBS leads at 0. 4% versus -9. 5% for SPT. At the gross margin level — before operating expenses — HUBS leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sprout Social, Inc.

(SPT) trades at 8. 0x forward P/E versus 15. 2x for HubSpot, Inc. — 7. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SPT: 675. 7% to $57. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, HubSpot, Inc.

(HUBS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01), +359. 7% 10Y return). Both have compounded well over 10 years (HUBS: +359. 7%, DSGN: -65. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SPT (Technology) and DSGN (Healthcare) and HUBS (Technology) and FULC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SPT is a small-cap quality compounder stock; DSGN is a small-cap quality compounder stock; HUBS is a mid-cap high-growth stock; FULC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.